Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Neoplasia ; 56: 101026, 2024 Jul 06.
Article in English | MEDLINE | ID: mdl-38972207

ABSTRACT

OBJECTIVES: There is an active debate regarding whether metformin use improves survival in people with ovarian cancer. We examined this issue using methods designed to avoid immortal time bias-as bias that occurs when participants in a study cannot experience the outcome for a certain portion of the study time. METHODS: We used time-dependent analyses to study the association between metformin use for all 4,951 patients diagnosed with ovarian cancer in 1997 through 2018 in the province of British Columbia, Canada. Cox proportional hazards models were run to estimate the association between metformin and survival in the full cohort of ovarian cancer patients and among a cohort restricted to patients with diabetes. RESULTS: Metformin use was associated with a 17 % better ovarian cancer survival in the full cohort (adjusted hazard ratio (aHR) = 0.83 (95 %CI 0.67, 1.02)), and a 16 % better ovarian cancer survival for serous cancers patient's cohort (aHR = 0.84 (95 %CI 0.66, 1.07)), although both were not significant. However, a statistically significant protective effect was observed when restricting to the diabetic cohort (aHR = 0.71 (95 %CI 0.54-0.91)), which was also seen among serous cancers (aHR = 0.73 (95 %CI 0.54-0.98)). CONCLUSION: Metformin use was associated with improved ovarian cancer survival. The lack of statistical significance in the full cohort may reflect that diabetes is associated with reduced cancer survival, and thus diabetes itself may offset the benefit of metformin when examining the full cohort. Future research should examine metformin use among non-diabetic ovarian cancer patients.

2.
Gynecol Oncol ; 139(3): 487-94, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26436478

ABSTRACT

OBJECTIVE: To define risk thresholds for cost-effectiveness of risk-reducing salpingo-oophorectomy (RRSO) for ovarian cancer (OC) prevention in low/intermediate risk postmenopausal women. METHODS: A decision-analytic model compares lifetime costs-&-effects of offering 'RRSO' with 'no RRSO' to postmenopausal women ≥50years for different lifetime OC-risk thresholds: 2%, 4%, 5%, 6%, 8% and 10%. Well established data from the literature are used to estimate total costs, effects in terms of Quality-Adjusted-Life-Years(QALYs), cancer incidence, incremental cost-effectiveness ratio(ICER) and impact. Costs are reported at 2012 prices; costs/outcomes discounted at 3.5%. Deterministic/probabilistic sensitivity analysis (PSA) evaluate model uncertainty. RESULTS: RRSO does not save QALYs and is not cost-effective at the 2% general population lifetime OC-risk. At 4% OC-risk RRSO saves QALYs but is not cost-effective. At risk thresholds ≥5%, RRSO saves more life-years and QALYs and is highly cost-effective. The ICERs for OC-risk levels 5%, 6%, 8% and 10% are £15,247, £9958, £4584, and £1864 respectively. The gain in life-years from RRSO equates to 29.2, 40.1, 62.1 and 80.3days at risk thresholds of 5%, 6%, 8% and 10% respectively. The results are not sensitive to treatment costs of RRSO/OC/cardiovascular events but are sensitive to utility-scores for RRSO. On PSA, 67%, 80%, 84%, 91% and 94% of simulations at risk thresholds of 4%, 5%, 6%, 8% and 10% respectively are cost-effective for RRSO. CONCLUSION: RRSO is highly cost-effective in postmenopausal women aged >50 with ≥5% lifetime OC-risk and increases life-expectancy by ≥29.2days. The results could have significant clinical implications given the improvements in risk prediction and falling costs of genotyping.


Subject(s)
Ovarian Neoplasms/prevention & control , Ovariectomy/economics , Salpingectomy/economics , Aged , Cost-Benefit Analysis , Decision Support Techniques , Female , Genes, BRCA1 , Genes, BRCA2 , Genotype , Health Care Costs , Humans , Middle Aged , Ovarian Neoplasms/genetics , Postmenopause , Quality-Adjusted Life Years , Risk Assessment/methods , Risk Factors
3.
J Neurovirol ; 19(6): 574-85, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24338243

ABSTRACT

This study aimed to explore the relationship of body mass index (BMI), waist circumference (WC), and waist-to-hip ratio (WHR) with cognition in women with (HIV+) and without HIV (HIV-) infection. One thousand six hundred ninety participants (1,196 HIV+, 494 HIV-) in the Women's Interagency HIV Study (WIHS) with data available on anthropometric measures comprise the analytical sample. Cross-sectional analyses using linear regression models estimated the relationship between anthropometric variables and Trails A, Trails B, Stroop interference time, Stroop word recall, Stroop color naming and reading, and Symbol Digit Modalities Test (SDMT) with consideration for age, HIV infection status, Wide Range Achievement Test score, CD4 count, insulin resistance, drug use, and race/ethnicity. Among HIV+ women, BMI < 18.5 kg/m(2) was associated with poorer cognitive performance evidenced by longer Trails A and Trails B and shorter SDMT completion times. An obese BMI (30 kg/m(2) or higher) was related to better performance on Trails B and worse performance on the Stroop interference test. Among HIV- women, an obese BMI was related to worse performance on the Stroop color naming test. Few and inconsistent associations were observed between WC, WHR, and cognition. Among women at mid-life with chronic (at least 10 years) HIV infection, common anthropometric measures, primarily BMI, were differentially related to cognitive test performance by cognitive domain. Higher levels of BMI were associated with better cognitive function. In this era of antiretroviral therapies, restoration of health evidenced as higher BMI due to effective antiretroviral therapies, may improve cognitive function in middle-aged HIV-infected women.


Subject(s)
Cognition Disorders/physiopathology , HIV Infections/physiopathology , HIV-1 , Adult , Age Factors , Body Mass Index , Case-Control Studies , Cognition , Cognition Disorders/etiology , Cognition Disorders/psychology , Cognition Disorders/virology , Executive Function , Female , HIV Infections/complications , HIV Infections/psychology , HIV Infections/virology , Humans , Memory , Middle Aged , Neuropsychological Tests , Prospective Studies , Severity of Illness Index , Task Performance and Analysis , Waist Circumference , Waist-Hip Ratio
4.
Int Arch Allergy Immunol ; 160(3): 233-40, 2013.
Article in English | MEDLINE | ID: mdl-23075813

ABSTRACT

BACKGROUND: The prevalence of IgE binding to the group 15 and 18 house dust mite (HDM) allergens of the Dermatophagoides species is reported to be >50% and they are the major allergens of HDM-sensitised dogs. The objective was to quantitate the IgE titres to Der p 15 and Der p 18 and evaluate their importance in human HDM sensitisation compared to the known major and mid-tier allergens. METHODS: Der p 15 and Der p 18 were produced in Pichia pastoris, and their structure validated by circular dichroism. IgE binding was measured in 37 Australian HDM-allergic adults using a quantitative DELFIA™ assay. RESULTS: The prevalence of IgE titres to Der p 15 and Der p 18 >0.1 ng/ml was low (38%) and only one subject had a titre >10 ng/ml to either allergen. The mean anti-Der p 15 and Der p 18 titres were 1.2 and 2.6 ng/ml, respectively, i.e. approximately 10- to 20-fold lower than the response to the major Der p 1 and Der p 2 allergens (p < 0.001). The IgE responses to Der p 15 and Der p 18 were lower than the mid-tier allergens Der p 5 and Der p 7 and although they correlated with each other, they did not correlate with titres to either the major or mid-tier allergens. CONCLUSIONS: Sensitisation to Der p 15 and Der p 18 makes a minor contribution to anti-HDM IgE titres, and the titres do not correlate with the size of the response to the major allergens.


Subject(s)
Antigens, Dermatophagoides/immunology , Arthropod Proteins/immunology , Chitinases/immunology , Hypersensitivity/immunology , Pyroglyphidae/immunology , Recombinant Proteins/immunology , Adult , Animals , Australia , Dogs , Female , Humans , Hypersensitivity/veterinary , Immunoglobulin E/immunology , Male , Middle Aged , Pichia/genetics , Protein Binding , Protein Conformation
5.
Addict Biol ; 17(1): 181-91, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21070507

ABSTRACT

Previous studies of the association of the C17T polymorphism of the mu opiate receptor gene with substance dependence compared cases with substance dependence to controls and usually found no significant association. However, the studies were limited by small sample size-no study had more than 12 subjects with the TT genotype, a genotype that is rare in white and Asian subjects. Moreover, drug use is not dichotomous but follows a spectrum from non-use to modest, intermittent use, to use several times daily. We asked whether the Kreek-McHugh-Schluger-Kellogg (KMSK) scales for alcohol, cocaine, opiates and tobacco that quantify substance use during the time of a subject's maximal use might be more sensitive measures than dichotomous outcomes. We administered the KMSK scales and completed C17T genotyping on 1009 human immunodeficiency virus (HIV)-infected and 469 HIV-uninfected women in The Women's Interagency HIV Study, an ongoing study of HIV in women. Forty-two of the 697 African American, 1 of the 182 Hispanic and none of the 161 white women had the TT genotype. KMSK cocaine, alcohol and tobacco scores were significantly higher in the African American women with the TT genotype (P = 0.008, 0.0001, and 0.006, respectively), but opiate scores were not. Ordinal regression models controlling for HIV serostatus, age, education, and income had odds ratios for the TT genotype for predicting alcohol, tobacco, cocaine and opiates scores of 2.1 (P = 0.02), 2.4 (P = 0.0004), 2.0 (P = 0.03) and 1.9 (P = 0.07). We conclude that the TT genotype of OPRM1 may increase the risk of substance use and abuse.


Subject(s)
Black or African American/genetics , Blood Proteins/genetics , Cytokines/genetics , Polymorphism, Genetic/genetics , Receptors, Opioid, mu/genetics , Substance-Related Disorders/genetics , Adult , Cohort Studies , Cross-Sectional Studies , Female , Humans , Middle Aged , Odds Ratio , Prospective Studies
6.
Thorax ; 67(4): 321-7, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22106019

ABSTRACT

BACKGROUND: Infants who develop house dust mite (HDM) allergy and HDM-sensitised children with severe persistent asthma have low antibody responses to the P6 antigen of Haemophilus influenzae. OBJECTIVE: To measure the development of antibody to two ubiquitous bacteria of the respiratory mucosa in a prospective birth cohort at high risk of allergic disease and to assess which responses are associated with asthma and atopy. METHODS: IgG1 and IgG4 antibody to H influenzae (P4 and P6) and Streptoccocus pneumoniae (PspA and PspC) surface antigens was measured in yearly blood samples of children aged 1-5 years. IgE to the P6 antigen was examined for the 5-year group. The children were stratified based on HDM sensitisation and asthma at 5 years of age. RESULTS: HDM-sensitised children had lower IgG1 antibody titres to the bacterial antigens, and early responses (<3 years and before the development of HDM sensitisation and asthma) corrected for multiple antigens were significantly reduced for P4, P6 and PspC (p=0.008, p=0.004 and p=0.028, respectively). Similar associations with asthma were also found (p=0.008, p=0.004 and p=0.032 for P4, P6 and PspC, respectively). The IgG4 antibody titre and prevalence were similar in both HDM-sensitised and non-sensitised groups, but sensitised children had a slower downregulation of the IgG4 response. Children with asthma (27/145 at 5 years) had lower anti-P6 IgE responses (p<0.05). CONCLUSIONS: HDM-sensitised children have early defective antibody responses to bacteria that are associated with asthma. Surprisingly, antibacterial IgE was associated with a reduced risk for asthma.


Subject(s)
Antibodies, Bacterial/immunology , Antibody Formation/immunology , Asthma/immunology , Haemophilus influenzae/immunology , Immunoglobulin E/immunology , Immunoglobulin G/immunology , Pyroglyphidae/immunology , Streptococcus pneumoniae/immunology , Animals , Antigens, Dermatophagoides/immunology , Chi-Square Distribution , Child, Preschool , Female , Humans , Infant , Male , Regression Analysis , Statistics, Nonparametric , Western Australia
7.
J Acquir Immune Defic Syndr ; 59(2): 149-54, 2012 Feb 01.
Article in English | MEDLINE | ID: mdl-22107817

ABSTRACT

OBJECTIVE: To compare neuropsychological scores in women infected with HIV, women infected with both HIV and hepatitis C, and uninfected subjects. BACKGROUND: Some, but not all, studies have demonstrated that dual infection with Hepatitis C virus (HCV) and HIV has worse effects on cognition than infection with HIV alone. DESIGN/METHODS: The Women's Interagency HIV Study is an ongoing prospective study of the natural history of HIV in women where participants are reevaluated every 6 months. In a cross-sectional analysis, we evaluated the effects of active HIV and HCV infections on scores on symbol-digit modalities test, the Stroop interference test, and trails A and B after controlling for age, ethnicity, education, depression, liver disease, and current or past substance abuse. RESULTS: Data were available for 1338 women-17.8 % had detectable hepatitis C virus and 67% were HIV seropositive. In fully adjusted general linear models, HCV viremia was not associated with scores on any of the cognitive tests. CONCLUSIONS: In this large sample of women, active HCV infection was not associated with scores on a small battery of neuropsychological tests.


Subject(s)
Cognition Disorders/virology , HIV Infections/complications , Hepatitis C/complications , Adult , Aged , Anti-HIV Agents/therapeutic use , Cognition Disorders/diagnosis , Cohort Studies , Cross-Sectional Studies , Female , HIV Infections/drug therapy , Hepatitis C/virology , Humans , Middle Aged , Multivariate Analysis , Neuropsychological Tests , Prospective Studies , Risk Factors , United States , Viral Load
8.
AIDS Educ Prev ; 21(3 Suppl): 81-93, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19537956

ABSTRACT

We have recently shown that cigarette smoking is associated with lesser responses to potent antiretroviral therapies. Certain Cytochrome P-450 enzymes activate compounds derived from tobacco smoke into toxic forms that may promote HIV-1 gene expression through promotion of DNA-adduct formation by the oxidation of chemical constituents of cigarette smoke, such as polyaromatic hydrocarbons and dioxins. To explore the association between environmental and genetic factors to viral replication in women who smoke and receive highly active anti-retroviral therapy (HAART), we assessed the impact of polymorphisms in a panel of four Cytochrome P-450 genes (CYP1A1, CYP2A6, CYP2D6, and CYP2E1) and two Glutathione S-transferase genes (GSTM1 and GSST1) in 924 participants of the Women's Interagency HIV Study (WIHS). Our findings showed that GSTM1 and GSST1 deletions were not associated with HAART effectiveness. By contrast, homozygosity for the CYP1A1-m1 polymorphism, was associated with impaired viral response to treatment among smokers (relative hazard (RH) = 0.54; 95% confidence interval = 0.31-0.94) after adjustment for pretreament viral load, CD4 count, age, hepatitis C infection, prior HAART therapy and race, although it had no effect among nonsmokers. We conclude that the association of the CPY1A1-m1 variant with a reduced response to HAART therapy in HIV infected smokers is consistent with this enzyme's role in the metabolic conversion of environmental toxins to DNA adducts, which may directly promote HIV-1 gene expression.


Subject(s)
Antiretroviral Therapy, Highly Active , Cytochrome P-450 CYP1A1/genetics , HIV Infections/drug therapy , Smoking/genetics , Virus Replication , Anti-HIV Agents/therapeutic use , CD4 Lymphocyte Count , Cohort Studies , DNA Adducts/genetics , Disease Progression , Female , Follow-Up Studies , Gene Expression , Genotype , Glutathione Transferase/genetics , HIV Infections/metabolism , HIV Infections/pathology , HIV-1 , Humans , Kaplan-Meier Estimate , Longitudinal Studies , Polymerase Chain Reaction , Polymorphism, Restriction Fragment Length , Prevalence , Proportional Hazards Models , Smoking/adverse effects , Treatment Outcome , Viral Load
9.
Mol Oncol ; 3(2): 171-81, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19383379

ABSTRACT

The value of identifying women with an inherited predisposition to epithelial ovarian cancer has become readily apparent with the identification of the BRCA1, and BRCA2 genes. Women who inherit a deleterious mutation in either of these genes have a very high lifetime risk of ovarian cancer (10-60%) and to some extent, increased risks of fallopian tube and peritoneal cancer. These highly lethal cancers are almost completely prevented by prophylactic salpingoophorectomy. BRCA1/2 mutation testing has become the accepted standard of care in families with a strong history of breast and/or ovarian cancer. This approach has the potential to reduce ovarian cancer mortality by about 10%. Although the ability to perform genetic testing for BRCA1 and 2 represents a significant clinical advance, the frequency of mutations in these high penetrance ovarian cancer susceptibility genes is low in most populations. There is evidence to suggest that ovarian cancer susceptibility might be affected by common low penetrance genetic polymorphisms like it was shown for several common disorders like diabetes or breast cancer. Although such polymorphisms would increase risk to a lesser degree, they could contribute to the development of a greater proportion of ovarian cancers by virtue of their higher frequencies in the population. It has been shown that the most powerful approach to studying low penetrance genes is an association study rather than a linkage study design. This review describes the efforts that have been made in this field by individual case-control studies and through multi-center collaborations as part of international consortia such as the Ovarian Cancer Association Consortium (OCAC).


Subject(s)
Ovarian Neoplasms/genetics , Polymorphism, Genetic , Case-Control Studies , Female , Genes, BRCA1 , Genes, BRCA2 , Genetic Predisposition to Disease , Humans , Multicenter Studies as Topic , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/prevention & control
10.
Cancer Res ; 69(6): 2349-57, 2009 Mar 15.
Article in English | MEDLINE | ID: mdl-19276375

ABSTRACT

The p53 protein is critical for multiple cellular functions including cell growth and DNA repair. We assessed whether polymorphisms in the region encoding TP53 were associated with risk of invasive ovarian cancer. The study population includes a total of 5,206 invasive ovarian cancer cases (2,829 of which were serous) and 8,790 controls from 13 case-control or nested case-control studies participating in the Ovarian Cancer Association Consortium (OCAC). Three of the studies performed independent discovery investigations involving genotyping of up to 23 single nucleotide polymorphisms (SNP) in the TP53 region. Significant findings from this discovery phase were followed up for replication in the other OCAC studies. Mixed effects logistic regression was used to generate posterior median per allele odds ratios (OR), 95% probability intervals (PI), and Bayes factors (BF) for genotype associations. Five SNPs showed significant associations with risk in one or more of the discovery investigations and were followed up by OCAC. Mixed effects analysis confirmed associations with serous invasive cancers for two correlated (r(2) = 0.62) SNPs: rs2287498 (median per allele OR, 1.30; 95% PI, 1.07-1.57) and rs12951053 (median per allele OR, 1.19; 95% PI, 1.01-1.38). Analyses of other histologic subtypes suggested similar associations with endometrioid but not with mucinous or clear cell cancers. This large study provides statistical evidence for a small increase in risk of ovarian cancer associated with common variants in the TP53 region.


Subject(s)
Genes, p53 , Ovarian Neoplasms/genetics , Adult , Aged , Alleles , Female , Genetic Predisposition to Disease , Humans , Linkage Disequilibrium , Middle Aged , Neoplasm Invasiveness , Ovarian Neoplasms/pathology , Polymorphism, Single Nucleotide , Young Adult
11.
J Allergy Clin Immunol ; 118(2): 361-7, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16890759

ABSTRACT

BACKGROUND: There are few studies that quantitatively compare IgE and IgG antibody binding to the major and minor house dust mite allergens. OBJECTIVE: To measure the IgE and IgG antibody specificities produced by adults and children, including children admitted to an emergency department for asthma. METHODS: Antibodies were measured by solid-phase microtiter assays. RESULTS: Children recruited from the emergency department had similar titers and patterns of IgE antibody binding compared with children without acute disease. Der p 1 and 2 bound 50% to 65% of the IgE antibody, and most of the remaining binding was to Der p 4, 5, and 7. Der p 3, 8, 10, and 20 induced low titers. The pattern was similar across a wide range of antihouse dust mite titers. IgG(1) and IgG(4) antibodies predominantly bound the major and midrange allergens and were mainly found in children with allergy. Children recruited in the emergency department had lower titers. CONCLUSION: The same IgE antibody-binding pattern and predominant contribution of Der p 1 and 2 was found across a wide range of total IgE antibody titers and for children admitted to an emergency department. IgG(1) and IgG(4) antibodies bound to the more allergenic specificities and were largely found in children with allergy. The IgG antibody titers were lower in sera from children admitted to the emergency department for asthma exacerbations. CLINICAL IMPLICATIONS: Der p 1 and 2 and possibly Der p 4, 5, and 7 provide a formulation suitable for immunotherapy and diagnosis. Low IgG antibodies were a feature of acute disease.


Subject(s)
Allergens/immunology , Antigens, Dermatophagoides/immunology , Hypersensitivity/immunology , Immunoglobulin E/immunology , Immunoglobulin G/immunology , Adolescent , Asthma/immunology , Child , Child, Preschool , Emergency Service, Hospital , Female , Humans , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...